Companies: 10,795·Total market cap: $144.5T
Landos Biopharma, Inc.

Landos Biopharma, Inc.

LABPNASDAQHealthcare
$22.93
+$0.13(+0.57%)
Market Cap$71675511
P/E Ratio—
52W High$22.94
52W Low$3.145
Cash on HandFinancialsRevenue

Landos Biopharma, Inc. (LABP) Cash on Hand — Cash & Short-Term Investments

Cash & cash equivalents plus short-term investments from the balance sheet, YoY change, and net cash vs debt context.

LABP · cash on hand · updated Dec 31, 2023

Core cash position

Cash & Short-Term Investments (CCE + ST Investments)
$37.5M▼ -15.4% vs prior year
FY · as of Dec 31, 2023 · Reported in USD
Cash & Cash Equiv. (CCE)
$37.5M
cashAndCashEquivalents
Short-Term Investments
$0
shortTermInvestments
YoY Change vs Prior Year
-15.4%
vs prior fiscal year
Latest Quarter
$29.1M
Q1 2024
Data Scope & Methodology

Cash on Hand = Cash & Cash Equivalents (CCE) + Short-Term Investments, as reported on the balance sheet (10-K/10-Q). Also referred to as cash reserves or cash position. Not free cash flow.

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · Reported in USD

Source: FMP /balance-sheet-statement · SEC 10-K / 10-Q · USDUpdated: December 31, 2023

Net cash vs debt

Cash & ST Investments$37.5MCash on Hand
Total Debt$0Total Debt
Net Cash / Net Debt+$37.5MNet Cash Position
Cash vs Debt Ratio
Cash 100%Debt 0%

Landos Biopharma, Inc. has a net cash position of $37.5M, holding more cash than debt.

Net Cash = Cash & ST Investments − Total Debt$37.5M − $0 = +$37.5M

Cash on hand history

YoY Increase
YoY Decrease
Latest Year
LABP annual cash on hand history · Cash & Short-Term Investments · Source: FMP /balance-sheet-statement

Annual cash on hand by year

DateCash & ST InvestmentsYoY Change
Dec 31, 2023Latest$37.5M-15.4%
Dec 31, 2022$44.4M-51.1%
Dec 31, 2021$90.9M+223.0%
Dec 31, 2020$28.1M-43.7%
Dec 31, 2019$50.0M+13817.8%
LABP cash on hand annual historical data · Cash & Short-Term Investments per balance sheet (10-K/10-Q) · Reported in USD · Source: FMP /balance-sheet-statement

Healthcare Sector Cash Reserves Comparison

#CompanyCash & ST Inv.Cash/MCap
#1
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated
UNH
$28.12B7.6%#2
Johnson & Johnson
Johnson & Johnson
JNJ
$20.10B3.6%#3
Eli Lilly and Company
Eli Lilly and Company
LLY
$7.27B0.7%#4
AbbVie Inc.
AbbVie Inc.
ABBV
$5.26B1.3%
#5
Landos Biopharma, Inc.
Landos Biopharma, Inc.YOU
LABP
$37.5M52.4%
Healthcare sector cash reserves · Source: FMP /balance-sheet-statement + /profile · Sorted by Cash desccompanies with most cash on hand →

About cash on hand & methodology

Landos Biopharma, Inc. (LABP) cash on hand as of December 31, 2023 is $37.5M, comprising $37.5M in cash and cash equivalents (CCE) plus $0 in short-term investments — reported as Landos Biopharma, Inc. cash and short-term investments on the balance sheet (10-K filing). Also referred to as Landos Biopharma, Inc. cash reserves or cash position.

Landos Biopharma, Inc. annual cash on hand history shows decreased -15.4% in 2023: decreased -15.4% in 2023. Landos Biopharma, Inc. cash reserves in 2023 reflect the company's capital allocation strategy.

Landos Biopharma, Inc. carries total debt of $0 against cash of $37.5M, resulting in a net cash position of +$37.5M. For the full balance sheet, see the Financials → Balance Sheet tab.

Figures tie to SEC 10-K/10-Q balance sheet disclosures and FMP /balance-sheet-statement where noted.
Financial statementsFree cash flowNet incomeRevenueMarket capP/E ratioEarningsPrice history

Frequently asked questions

LABP cash on hand · 5 questions

As of December 31, 2023, Landos Biopharma, Inc. (LABP) has $37,549,000 in cash on hand — defined as cash and short-term investments on the balance sheet. This includes $37,549,000 in cash and cash equivalents (CCE) plus $0 in short-term investments. Latest quarter (March 31, 2024): $29,054,000. Data sourced from the annual 10-K filing via FMP.

LABP cash on handLABP cash reservesLABP cash 2023how much cash does LABP have

▸ Source: FMP /balance-sheet-statement · US GAAP · Landos Biopharma, Inc. · Landos Biopharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: December 31, 2023